ORCID Profile
0000-0002-7070-9387
Current Organisations
KU Leuven
,
Katholieke Universiteit Leuven
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 06-02-2018
DOI: 10.1111/DMCN.13652
Abstract: To systematically review evidence for pharmacological/neurosurgical interventions for managing dystonia in in iduals with cerebral palsy ( CP ) to inform a care pathway. Searches included studies with a minimum of five participants with dystonia in CP receiving oral baclofen, benzodiazepines (clonazepam, diazepam, lorazepam), clonidine, gabapentin, levodopa, trihexyphenidyl, botulinum toxin, intrathecal baclofen ( ITB ), or deep brain stimulation ( DBS ). Evidence was classified according to American Academy of Neurology guidelines. Twenty‐eight articles underwent data extraction: one levodopa, five trihexyphenidyl, three botulinum toxin, six ITB , and 13 DBS studies. No articles for oral baclofen, benzodiazepines, clonidine, or gabapentin met the inclusion criteria. Evidence for reducing dystonia was level C (possibly effective) for ITB and DBS level C (possibly ineffective) for trihexyphenidyl and level U (inadequate data) for botulinum toxin. For dystonia reduction, ITB and DBS are possibly effective, whereas trihexyphenidyl was possibly ineffective. There is insufficient evidence to support oral medications or botulinum toxin to reduce dystonia. There is insufficient evidence for pharmacological and neurosurgical interventions to improve motor function, decrease pain, and ease caregiving. The majority of the pharmacological and neurosurgical management of dystonia in CP is based on clinical expert opinion. Intrathecal baclofen and deep brain stimulation are possibly effective in reducing dystonia. Current evidence does not support effectiveness of oral medications or botulinum toxin to reduce dystonia. Evidence is inadequate for pharmacological/neurosurgical interventions impact on improving motor function, pain/comfort, and easing caregiving. The majority of the care pathway rests on expert opinion.
Publisher: Informa UK Limited
Date: 25-09-2018
DOI: 10.1080/17518423.2018.1519609
Abstract: This study aims to identify eye-gaze control technology outcomes, parent perception of the technology and support received, and gauge the feasibility of available measures. Five children with dyskinetic cerebral palsy, mean age 4 years, 4 months (1 year, 0 months) n = 4 males trialled two eye-gaze control technology systems, each for six weeks. Parents completed pre- and post-questionnaires. Parents found the 6-week home-based trial period to be the right length. Written guidelines and instructions about set-up, calibration, and play and learning activities were perceived as important. Children demonstrated improvements in goal achievement and performance. Parents found questionnaires on quality of life, participation, behaviours involved in mastering a skill and communication outcomes challenging to complete resulting in substantial missing data. Eye-gaze control technology warrants further investigation for young children with dyskinetic cerebral palsy in a large international study.
Publisher: Springer Science and Business Media LLC
Date: 10-02-2021
DOI: 10.1186/S12883-021-02077-Z
Abstract: Limited research exists to guide clinical decisions about trialling, selecting, implementing and evaluating eye-gaze control technology. This paper reports on the outcomes of a Delphi study that was conducted to build international stakeholder consensus to inform decision making about trialling and implementing eye-gaze control technology with people with cerebral palsy. A three-round online Delphi survey was conducted. In Round 1, 126 stakeholders responded to questions identified through an international stakeholder Advisory Panel and systematic reviews. In Round 2, 63 respondents rated the importance of 200 statements generated by in Round 1. In Round 3, 41 respondents rated the importance of the 105 highest ranked statements retained from Round 2. Stakeholders achieved consensus on 94 of the original 200 statements. These statements related to person factors, support networks, the environment, and technical aspects to consider during assessment, trial, implementation and follow-up. Findings reinforced the importance of an in idualised approach and that information gathered from the user, their support network and professionals are central when measuring outcomes. Information required to support an application for funding was obtained. This Delphi study has identified issues which are unique to eye-gaze control technology and will enhance its implementation with people with cerebral palsy.
No related grants have been discovered for Elegast Monbaliu.